The Effect of Metformin on Hypothalamic-Pituitary-Thyroid Axis Activity in Women with Interferon-Induced Hypothyroidism: A Pilot Study

Abstract

Background: One of the most frequent adverse effects of interferon-α therapy is thyroiditis. Metformin was found to improve insulin sensitivity in hepatitis C patients, as well as to reduce elevated thyrotropin levels in patients with hypothyroidism. The aim of this study was to investigate the effect of metformin on hypothalamic-pituitary-thyroid axis activity in patients with interferon-induced thyroiditis.

Methods: The study included 2 matched groups of women with type 2 diabetes and untreated subclinical hypothyroidism: patients with interferon-induced thyroiditis (n=8) and patients with Hashimoto’s thyroiditis (n=12). Fasting plasma glucose, the homeostatic model assessment 1 of insulin resistance ratio (HOMA1-IR), glycated hemoglobin, the estimated glomerular filtration rate, as well as serum levels of thyrotropin, thyroid hormones, prolactin and insulin-like growth factor-1 (IGF-1) were assessed at baseline and after 4 months of metformin treatment.

Results: Apart from reducing plasma glucose, HOMA1-IR and glycated hemoglobin, metformin decreased serum levels of thyrotropin. Circulating levels of thyroid hormones, prolactin and IGF-1 remained at a similar level throughout the study. The effect of metformin on serum thyrotropin was stronger in patients with interferon-induced thyroiditis than in patients with Hashimoto’s thyroiditis, as well as correlated with its impact on insulin sensitivity.

Conclusions: Our results indicate that metformin may be an effective agent in patients with interferon-induced hypothyroidism.

Key words

interferon-α - hepatitis C - metformin - hypothalamic-pituitary-thyroid axis

• References

• 1 Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. Expert Rev Gastroenterol Hepatol 2011; 5: 503-516
• 2 Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes 2014; 5: 52-58
• 3 American Diabetes Association . Standards of medical care in diabetes – 2015. Approaches to glycemic treatment. Diabetes Care 2015; 38 (Suppl. 01) S42-S48
• 4 Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008; 5: 157-167
• 5 Hsu CS, Hsu SJ, Lin HH et al. A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. J Formos Med Assoc 2014; 113: 716-721
• 6 Romero-Gómez M, Diago M, Andrade RJ et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-1708
• 7 García-Ruiz I, Solís-Muñoz P, Gómez-Izquierdo E et al. Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice. J Biol Chem 2012; 287: 19564-19573
• 8 Nkontchou G, Cosson E, Aout M et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96: 2601-2608
• 9 Menconi F, Hasham A, Tomer Y. Environmental triggers of thyroiditis: hepatitis C and interferon-α. J Endocrinol Invest 2011; 34: 78-84
• 10 Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 2009; 23: 703-712
• 11 Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010; 34: J322-J326
• 12 Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006; 91: 225-227
• 13 Cappelli C, Rotondi M, Pirola I et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 2009; 32: 1589-1590
• 14 Isidro ML, Penín MA, Nemiña R et al. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 2007; 32: 79-82
• 15 Morteza Taghavi S, Rokni H, Fatemi S. Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diab Vasc Dis Res 2011; 8: 47-48
• 16 Lupoli R, Di Minno A, Tortora A et al. Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J Clin Endocrinol Metab 2014; 99: E143-E148
• 17 Krysiak R, Okopien B. The effect of metformin on the hypothalamic-pituitary-thyroid axis in women with polycystic ovary syndrome and subclinical hypothyroidism. J Clin Pharmacol 2015; 55: 45-49
• 18 Krysiak R, Okopien B. Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone. Clin Endocrinol 2011; 75: 404-406
• 19 Cappelli C, Rotondi M, Pirola I et al. Metformin-induced thyrotropin suppression is not associated with cardiac effects. Hormones (Athens) 2014; 13: 252-258
• 20 Krysiak R, Szkrobka W, Okopien B. The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and subclinical hyperthyroidism. Exp Clin Endocrinol Diabetes 2015;
• 21 Oleandri SE, Maccario M, Rossetto R et al. Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. J Endocrinol Invest 1999; 22: 134-140
• 22 Labbuzek K, Suchy D, Gabryel B et al. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010; 62: 956-965
• 23 Krysiak R, Okrzesik J, Okopien B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine 2014;
• 24 Oride A, Kanasaki H, Purwana IN et al. Effects of metformin administration on plasma gonadotropin levels in women with infertility, with an in vitro study of the direct effects on the pituitary gonadotrophs. Pituitary 2010; 13: 236-241
• 25 Genazzani AD, Battaglia C, Malavasi B et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 114-119
• 26 Weissenborn K, Ennen JC, Bokemeyer M et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006; 55: 1624-1630
• 27 Felger JC, Li L, Marvar PJ et al. Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun 2013; 31: 153-160
• 28 Brabant G, Ocran K, Ranft U et al. Physiological regulation of thyrotropin. Biochimie 1989; 71: 293-301
• 29 Cappelli C, Rotondi M, Pirola I et al. Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol 2012; 167: 261-265
• 30 Krysiak R, Gdula-Dymek A, Okopień B. Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol Rep 2013; 65: 429-434
• 31 Krysiak R, Gdula-Dymek A, Okopień B. Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol Rep 2013; 65: 1311-1316
• 32 Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011; 107: 1010-1018
• 33 Ittermann T, Markus MR, Schipf S et al. Metformin inhibits goitrogenous effects of type 2 diabetes. Eur J Endocrino 2013; 169: 9-15
• 34 Rezzónico J, Rezzónico M, Pusiol E et al. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord 2011; 9: 69-75
• 35 Chen G, Xu S, Renko K et al. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 2012; 97: E510-E512
• 36 López M, Varela L, Vázquez MJ et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010; 16: 1001-1008
• 37 Duntas LH, Orgiazzi J, Brabant G. The interface between thyroid and diabetes mellitus. Clin Endocrinol 2011; 75: 1-9
• 38 Chau-Van C, Gamba M, Salvi R et al. Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 2007; 148: 507-511
• 39 Szybiński Z. Polish Council for Control of Iodine Deficiency Disorders. Work of the Polish Council for Control of Iodine Deficiency Disorders, and the model of iodine prophylaxis in Poland. Endokrynol Pol 2012; 63: 156-160